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to explain the rise in Cr and ≥10% rise in serum cystatin levels from
baseline at 24 h. Cr will be assessed at baseline and at 24, 48 and
72 h and CyC will be measured at baseline and at 24 h.
Results: After 48 hrs of CM exposure, Cr increase ≥0.5 mg/dL
occurred in 29 patients (11.3%) whereas increase in CyC ≥10% at
24 hrs after CM exposure occurred in 66 patients (26.08%). The
difference in mean Cr and baseline, 24 hrs and 48 hrs after CM
exposure was not statistically signiﬁcant whereas that between
CyC at baseline and 24 h after CM exposure was signiﬁcant. CyC
detected CIN 24 hrs earlier as compared to Cr. Similarly the dif-
ference between GFR calculated by Cr equation was not statisti-
cally signiﬁcant between pre and post CM exposure but the
difference was signiﬁcant when GFR was calculated using the
combined equation. The risk of CIN was higher in patients with
pre-existing CKD, diabetes, advanced age, haemodynamic instabil-
ity, heart failure (LVEF < 40%), patients with ACS and higher con-
trast volumes.
Conclusions: The assessment of CyC at 24 hours after CM exposure
allows an early diagnosis of CIN. Also CyC equation and the
combined equation (Cr + CyC) for measurement of GFR accurately
identiﬁed the patients with CIN even at 24 hrs after CM exposure,
in contrast to Creatinine which took 48-72 hrs. Hence the manage-
ment strategies for CIN can be started earlier by 24-48 hrs when
CyC is used as a marker for CIN which would improve long term
outcomes.
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Background: Pulmonary embolism (PE) is one of themajor cause of
cardiovascular mortality. High index of suspicion is necessary for
diagnosis. PE likelihood scoring is a useful clinical tool for risk
stratiﬁcation and management. This was a prospective registry to
study the clinical features, clinical likelihood scoring, risk strati-
ﬁcation and management of PE.
Methods: Consecutive cases hospitalized over a period of 3 years
were studied. Revised Geneva score was applied to all cases of
suspected pulmonary embolism. Most cases had PE conﬁrmed by
CT pulmonary angiography. Risk stratiﬁcation (Pulmonary Embo-
lism Severity Index from 2015) was used to guide the treatment
strategy.
Results: There were 44 patients of pulmonary embolism, 26 being
male. The mean age for male patients was 43.8 years and for
females 55.4 years. Among 44 patients, 11 (25.0%) patients had
surgery or immobilisation in the past 30 days, 15 (34.09%) patients
had DVT. 4 (9.09%) patients had diabetes, 3 (6.81%) had hyperten-
sion. 6 (13.6%) patients were smokers. 37 (84.0%) patients had
breathlessness. ECG revealed sinus tachycardia in 34 (77.2%). Echo-
cardiogram showed dilated right atrium (RA) & right ventricle (RV)
in 32 (72.7%) patients and RV dysfunction in 10 (22.7%) patients.
The mean modiﬁed Geneva score was 8.18 for males and 9.7 for
female. CT pulmonary angiography was done in 33 patients which
conﬁrmed PE in 32 cases. Risk stratiﬁcation according to expected
pulmonary embolism-related early mortality rate stratiﬁed 11
(25.0%) patients in high risk group, 27 (61.3%) patients in inter-
mediate risk group & 6 (13.6%) patients in low risk group. 27 (61.3%)
patients were thrombolysed with tenecteplase & 3 (6.8%) with
reteplase. 1 patient had emergency surgical thrombo-endartect-
omy, recovering fully after an eventful post-operative period. Post-
treatment most patients showed improvement.
Conclusion: Modiﬁed Geneva score along with imaging investiga-
tions helped in establishing diagnosis. Thrombolytic therapy in
high risk cases and selected intermediate risk cases was safe and
effective.
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Background: It is well proven that sildenaﬁl improves pulmonary
hemodynamics and exercise capacity in patients with primary
pulmonary hypertension. However, the drug armamentarium
for secondary pulmonary hypertension is limited. Sildenaﬁl may
also be helpful in this subgroup. Certain studies have shown
promising results but none of the magnitude to promulgate new
recommendations.
Methods: In this double-blind, placebo-controlled study, we ran-
domly assigned 106 patients with symptomatic secondary PAH
(idiopathic DCMP, heart failure with preserved EF, COPD, and other
lung parenchymal disease, valvular heart disease) to placebo or
sildenaﬁl (53 in each group). Sildenaﬁl was given orally 25 mg TID
for 6 weeks. The primary end point was the change from baseline
to week 6 in the distance walked in 6 minutes. We also assessed
clinical improvement (improvement in 6 minute walk test, and
NYHA functional class, change in Borg dyspnoea index) and
change in hemodynamic parameters (PASP, LVEF).
Results: Of the 106 patients, included secondary PAH was due to
COPD in 21 (19.8%), valvular heart disease in 53 (50%), heart failure
with preserved EF in 16 (15%), idiopathic DCMP in 11 (10.2%) and
other lung parenchymal diseases in 5 (5%). The mean increase in
the distance walked after 6 weeks of therapy was 54 min sildenaﬁl
group and 13 m in placebo group p = 0.04. In the sildenaﬁl group
signiﬁcantly greater number of patients improved by at least one
functional class (23% vs 11%, p = 0.003). The mean NYHA class at 6
weeks was 2.0  0.2 in the sildenaﬁl group versus 2.8  0.4 in the
placebo group, p = 0.02. The mean PASP signiﬁcantly decreased in
the sildenaﬁl group at 6 weeks (48  6 mmHg), compared to pla-
cebo (58  6 mmHg), p = 0.02. LVEF was higher in the sildenaﬁl
group, 60  10% versus 55  10% in the placebo group, but did
not reach statistically signiﬁcant difference.
Conclusion: Sildenaﬁl improves exercise capacity, functional class,
and hemodynamics in patients with PAH. PDE-5 inhibition may
represent an important therapy for patients with secondary PAHif,
the beneﬁts observed in our study are conﬁrmed in larger clinical
trials.
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Background: Atrial ﬁbrillation increases the risks of stroke and
death. Although warfarin reduces the risks of stroke and death, it
increases the risk of hemorrhage along with its other drawbacks.
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Dabigatran is a new oral direct thrombin inhibitor and has been
proposed to overcome many pitfalls of warfarin therapy.
Method: In this study, we retrospectively studied 236 patients who
had atrial ﬁbrillation and were at risk of stroke who received ﬁxed
dose of Dabigatran 110 mg and adjusted-dose warfarin. Patients
were followed up for a period of 2 years and stroke or systemic
embolism was our primary end points.
Results: When rates of the primary outcome were considered
which was 1.56% per year in the warfarin group, as compared with
1.33% per year in the group that received 110 mg of dabigatran
(relative risk with dabigatran, 0.90; 95% conﬁdence interval [CI],
0.72–1.09; p < 0.001 for non inferiority). Again the rate of major
bleeding was 2.96% per year in the warfarin group, as compared
with 2.11% per year in the group receiving 110 mg of dabigatran
( p = 0.005). If the rate of hemorrhagic stroke was considered, it was
0.34% per year in the warfarin group, as compared with 0.09% per
year with 110 mg of dabigatran ( p < 0.003). Finally the mortality
rate was 3.9% per year in the warfarin group, as compared with
3.15% per year with 110 mg of dabigatran ( p = 0.11)
Conclusions:We observed in our study that, dabigatran given at a
dose of 110 mg was associated with rates of stroke and systemic
embolism that were similar and were non inferior to those asso-
ciated with warfarin, as well as lower rates of major hemorrhage.
Alsomany pitfalls of warfarinwere coveredwell by Dabigatran and
hence it's use in patients of atrial ﬁbrillation with risk of stroke can
be advocated.
Effect of vanadium supplementation on
high fat diet induced hyperlipidemia
G. Subramanyam1,*, Ramalingam2,
Veeranjaneyulu 3
1Department of Cardiology, Narayana Medical Institutions, Chinta Reddy
Palem, Nellore, India
2Department of Biochemistry, Narayana Medical Institutions, Chinta
Reddy Palem, Nellore, India
3Animal Lab, Narayana Medical Institutions, Chinta Reddy Palem,
Nellore, India
Inmicamineworkers in Nellore district the prevalence of ischemic
heart disease and serum cholesterol levels are less in when com-
pared to other rural population in our earlier studies. Vanadium
content of mica and Blood levels of vanadium in mica workers is
high compared to other rural population. Hence study in experi-
mental animals is under taken in our laboratory to know the effect
of vanadium.
Vanadium is an essential trace elements in certain animals and its
role in humans is debated. Under physiological conditions vana-
dium predominantly exists in either an anionic form (vanadate) or
a cationic form vanadyl. The vanadate is mainly bound to trans-
ferin and to a lesser extent to albumin. The present study aimed to
know the effect of vanadium supplementation on high fat diet
induced hyperlipidemia in experimental animals. In this study,
New Zealand white breed male rabbits divided into three groups
and each group consists of 6 in number.
Group I: Rabbits fed with standard diet.
Group II: Fed with 2% cholesterol diet.
Group III: Rabbits fed with group II diet and supplemented with
0.75 mg/kg of elemental vanadium as Sodium meta vanadate.
Total cholesterol, LDL cholesterol and triglycerides were signiﬁ-
cantly decreased in Group III when compared to Group II after the
experiment. HDL is similar in both groups. Present study shows
antilipedemic effect of Vanadium in experimental rabbits. Supple-
mentation of vanadiummay prevent cardiovascular risk factor like
Hyperlipidemia.
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Introduction: ST2 is a biomarker which is a member of the inter-
leukin (IL)-1 receptor family and exists in two forms, a trans-
membrane receptor (ST2L) as well as a soluble decoy receptor
(sST2). Myocytes that are subjected to mechanical stress secrete
ST2, that is associated with HF after STEMI.
Aims & objectives: To co-relate the level of ST2 on presentation
and at discharge, with the clinical severity of the disease on
presentation, the subsequent complications of ACS during the
hospital stay and the occurrence of heart failure/adverse cardio-
vascular events (re-infarction/death) after discharge.
Inclusion & exclusion criteria:
1. Age more than 30 years.
2. Presenting within 24 hours of onset of symptoms.
3. Fulﬁlling the criteria for diagnosis of Acute MI.
4. Patients with PCI related and CABG related acute MI have been
excluded.
Materials and methods: A prospective study is being done in
patients admitted with ACS in Apollo hospital Chennai. Blood
samples for ST2 are taken on presentation & at discharge. The
sample is analysed using the 'Presage kit' provided by Critical
diagnostics-Chennai Medipoint. A cut off of 35 ng/dl was used to
label a sample as high ST2 level. Clinical history, biochemical tests
and Echocardiography results are also documented.
Results: 42 patients admitted in Apollo Hospital, Chennai have
been included so far. The clinical proﬁle, ST2 levels, the clinical
outcome and re-hospitalisations (if any) were documented.
Conclusion: The study is still in process and concrete conclusions
cannot be drawn based on the existing samples. However high ST2
values were seen to be associated with increased mortality.
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Introduction: Cardiovascular (CV) involvement is common and a
signiﬁcant cause of morbidity and mortality in systemic lupus
erythematosus (SLE). Auto-antibodies anti-dsDNA and antipho-
spholipids antibodies (APLA) are both pathogenic as well as serve
a role as biomarker for diagnosis and severity. There are only very
few reports of correlation of anti-dsDNA and/or APLA positivity
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